Stock Details
NVS is Novartis AG's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 80.12$. Average daily volumn in 3 months 2.35M. Market cap 194.04B



Stock symbol : NVS. Exchange : NYSE. Currency : USD
Lastest price : 89.82$. Total volume : 1.47M. Market state PREPRE
Click reload if you want to check the lastest price on market!!!

Novartis AG (NVS)
Last Price
89.82$
Change
0.26
Volume
1.47M

Previous Close89.56
Open89.72
Day Range89.46-89.96
Bid0.00 x 1.2k
Ask0.00 x 1k
Volume1.47M
Average Volume2.35M
Market Cap194.04B
Beta0.51
52 Week Range74.09-94.26
Trailing P/E9.26
Foward P/E14.01
Dividend (Yield %)3.81%
Ex-Dividend Date2022-03-08



Financial Details


According to Novartis AG's financial reports the company's revenue in 2021 were 52.88B an increase( +6.12%) over the years 2020 revenue that were of 49.9B. In 2021 the company's total earnings were 24.02B while total earnings in 2020 were 8.07B( +200%).


Loading ...



Organization

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form me... dicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Market Cap:
194.04B
Revenue:
52.88B
Total Assets:
131.79B
Total Cash:
12.41B



News about "Novartis AG"

Novartis AG (NYSE:NVS) Is Down -0.13% Year To Date; Analysts Say It Will Rally

Source from : stocksregister - 2 days ago

Novartis AG (NYSE:NVS) price is hovering higher on Wednesday, November 30, jumping 0.50% above its previous close. A look at today’s price movement shows that the recent level at last check reads $87.See details»


Novartis AG's (VTX:NOVN) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Source from : Yahoo Finance - 6 days ago

Novartis (VTX:NOVN) has had a great run on the share market with its stock up by a significant 5.6% over the last month. Given that stock prices are usually aligned with a company's financial ...See details»


novartis-nvs-set-to-advance-malaria-drug-into-phase-iii-image

Novartis (NVS) Set to Advance Malaria Drug Into Phase III

Source from : YAHOO!Finance - 8 days ago

Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.See details»


With 53% ownership, Novartis AG (VTX:NOVN) boasts of strong institutional backing

Source from : Yahoo - 25 days ago

If you want to know who really controls Novartis AG (VTX:NOVN), then you'll have to look at the makeup of its share registry. With 53% stake, institutions possess the maximum shares in the company.See details»


Novartis Considers Sale Of Ophthalmology, Respiratory Units : Report

Source from : Nasdaq - 16 days ago

Novartis said in August that it planned to separate Sandoz, its generics and biosimilars division, into a new publicly traded standalone company through a 100 percent spin-off. Bloomberg reported ...See details»


Novartis Weighs Ophthalmology, Respiratory Unit Sales

Source from : Bloomberg L.P. - 16 days ago

Novartis AG is weighing sales of non-core assets as it seeks to raise money to invest in cutting-edge medicines, people familiar with the matter said. The Swiss pharmaceutical giant is in the ...See details»


Novartis weighs sale of ophthalmology, respiratory units - Bloomberg

Source from : Reuters - 16 days ago

REUTERS/Brian Snyder/File Photo Nov 16 (Reuters) - Swiss drugmaker Novartis AG (NOVN.S) is considering selling its ophthalmology and respiratory units, a Bloomberg report said on Wednesday ...See details»


Novartis AG

Source from : Wall Street Journal - 7 days ago

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...See details»


Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH

Source from : Business Insider - 10 days ago

and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of ...See details»


Novartis claims two firms are infringing its patent for multiple sclerosis drug

Source from : The Irish Times - 10 days ago

Switzerland-based Novartis AG, and its Irish affiliate, Novartis Ireland Ltd, claim Accord and Mylan are breaching their patent on Gilenya.The medicine is used in the treatment of relapsing ...See details»


Novartis Pharma AG: New long-term Leqvio (inclisiran) data from Novartis show sustained efficacy and safety over four years

Source from : Finanznachrichten - 24 days ago

and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of ...See details»


Novartis adds 50 million euros to European antibiotics investment budget

Source from : Yahoo News - 25 days ago

(Reuters) -Sandoz, the generic drugs business that will be spun off its parent Novartis, will boost investment in its European antibiotics production network by 50 million euros ($50 million) on ...See details»


Novartis weighs sale of ophthalmology, respiratory units - Bloomberg

Source from : Yahoo News - 16 days ago

(Reuters) -Swiss drugmaker Novartis AG is considering selling its ophthalmology and respiratory units, a Bloomberg report said on Wednesday, citing people familiar with the matter. The company is ...See details»


Novartis Considers Sale Of Ophthalmology, Respiratory Units : Report

Source from : Business Insider - 16 days ago

(RTTNews) - Novartis AG (NVS) is considering sales of non-core assets. It is in the early stages of considering options for its ophthalmology and respiratory units. Some private equity firms are ...See details»